{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:03:00Z","timestamp":1788825780052,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13555-023-01012-z","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:01:56Z","timestamp":1694750516000},"page":"2859-2868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02207231","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02207244","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-8567","authenticated-orcid":false,"given":"Ana-Maria","family":"Orbai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-3938","authenticated-orcid":false,"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"issue":"8","key":"1012_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1012_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1012_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3899\/jrheum.190923","volume":"48","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Liu M, Rebello S, et al. Association of nail psoriasis with disease activity measures and impact in psoriatic arthritis: data from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. J Rheumatol. 2021;48(4):520\u20136.","journal-title":"J Rheumatol"},{"issue":"1","key":"1012_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/1756-185X.14442","volume":"26","author":"G Cengiz","year":"2023","unstructured":"Cengiz G, Nas K, Keskin Y, et al. The impact of nail psoriasis on disease activity, quality of life, and clinical variables in patients with psoriatic arthritis: a cross-sectional multicenter study. Int J Rheum Dis. 2023;26(1):43\u201350.","journal-title":"Int J Rheum Dis"},{"key":"1012_CR5","unstructured":"Tremfya: package insert. Horsham: Janssen Biotech, Inc.; 2022. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf."},{"issue":"10230","key":"1012_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"issue":"10230","key":"1012_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"3","key":"1012_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1012_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1012_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","volume":"154","author":"P Foley","year":"2018","unstructured":"Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2018;154(6):676\u201383.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1012_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","volume":"49","author":"P Rich","year":"2003","unstructured":"Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1012_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1012_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/JDN.0000000000000418","volume":"10","author":"LM Aldredge","year":"2018","unstructured":"Aldredge LM, Higham RC. Manifestations and management of difficult-to-treat psoriasis. J Dermatol Nurses\u2019 Assoc. 2018;10(4):189\u201397.","journal-title":"J Dermatol Nurses' Assoc"},{"key":"1012_CR14","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1136\/annrheumdis-2020-eular.1333","volume":"79","author":"K Reich","year":"2020","unstructured":"Reich K, Dutz J, Foley P, et al. AB0759: Four-year efficacy and safety of guselkumab in psoriasis patients with and without psoriatic arthritis: a pooled analysis from VOYAGE 1 and VOYAGE 2. Ann Rheum Dis. 2020;79:1677.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1012_CR15","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146\u201359.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1012_CR16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","volume":"155","author":"T Terui","year":"2019","unstructured":"Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;155(10):1153\u201361.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1012_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights For Treatment (UPLIFT) Survey. Dermatol Ther (Heidelb). 2022;12(1):61\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1012_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002195","volume":"8","author":"CT Ritchlin","year":"2022","unstructured":"Ritchlin CT, Mease PJ, Boehncke WH, et al. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open. 2022;8(1): e002195.","journal-title":"RMD Open"},{"issue":"3","key":"1012_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475\u201385.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1012_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjd.17403","volume":"181","author":"M Augustin","year":"2019","unstructured":"Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358\u201365.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1012_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5114\/pdia.2016.62287","volume":"35","author":"P Lakuta","year":"2018","unstructured":"Lakuta P, Marcinkiewicz K, Bergler-Czop B, et al. Associations between site of skin lesions and depression, social anxiety, body-related emotions and feelings of stigmatization in psoriasis patients. Postepy Dermatol Alergol. 2018;35(1):60\u20136.","journal-title":"Postepy Dermatol Alergol"},{"issue":"6","key":"1012_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","volume":"76","author":"MC Pasch","year":"2016","unstructured":"Pasch MC. Nail psoriasis: a review of treatment options. Drugs. 2016;76(6):675\u2013705.","journal-title":"Drugs"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01012-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T10:10:27Z","timestamp":1698487827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01012-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1012"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01012-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ana-Maria Orbai has received grant\/research support from AbbVie, Amgen, Celgene, Eli Lilly, Horizon, Novartis, and Janssen; and consulting fees from Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Soumya D Chakravarty is an employee of Janssen Scientific Affairs, LLC and owns stock or stock options in Johnson & Johnson. Yin You is an employee of Janssen Research & Development, LLC. Ya-Wen Yang is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson. May Shawi is an employee of Janssen Research & Development, LLC, and owns stock in Johnson & Johnson. Joseph F Merola is a consultant and\/or investigator for AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies were conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practices. The governing ethical bodies for each of the participating sites approved the VOYAGE-1 and -2 study protocols, and all patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}